Trade Names:
Synonyms:
Status: Approved (2007)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L01EG01
UNII: 624KN6GM2T

Structure

InChI Key CBPNZQVSJQDFBE-FUXHJELOSA-N
Smile CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
InChI
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C56H87NO16
Molecular Weight 1030.3
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
INHIBITOR FK506-binding protein 1A inhibitor DailyMed
Primary Target
mechanistic target of rapamycin kinase

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Carcinoma, Renal Cell 4 D002292 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Rhabdomyosarcoma, Embryonal 3 D018233 ClinicalTrials
Hepatoblastoma 3 D018197 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Neoplasm Metastasis 3 D009362 ClinicalTrials
Rhabdomyosarcoma, Alveolar 3 D018232 ClinicalTrials
Lymphoma, Mantle-Cell 3 D020522 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Gliosarcoma 2 D018316 ClinicalTrials
Arthritis, Rheumatoid 2 D001172 ClinicalTrials
Small Cell Lung Carcinoma 2 D055752 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Ischemia 2 D007511 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Neuroblastoma 2 D009447 ClinicalTrials
Osteosarcoma 2 D012516 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Multiple Sclerosis, Relapsing-Remitting 2 D020529 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Adenoma 2 D000236 ClinicalTrials
Peripheral Arterial Disease 2 D058729 ClinicalTrials
Carcinoma, Islet Cell 2 D018273 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Somatostatinoma 2 D013005 ClinicalTrials
Insulinoma 2 D007340 ClinicalTrials
Ganglioneuroblastoma 2 D018305 ClinicalTrials
Retroviridae Infections 2 D012192 ClinicalTrials
Central Nervous System Neoplasms 2 D016543 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Carcinoma, Endometrioid 2 D018269 ClinicalTrials
Thyroid Neoplasms 2 D013964 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Kidney Neoplasms 2 D007680 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Myelodysplastic Syndromes 2 D009190 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma, Hepatocellular 2 D006528 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Oligodendroglioma 1 D009837 ClinicalTrials
Brain Neoplasms 1 D001932 ClinicalTrials
Breast Neoplasms, Male 1 D018567 ClinicalTrials
Adenocarcinoma 1 D000230 ClinicalTrials
Carcinoma 1 D002277 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 D015464 ClinicalTrials
Colorectal Neoplasms 1 D015179 ClinicalTrials
Prostatic Neoplasms 1 D011471 ClinicalTrials
Astrocytoma 1 D001254 ClinicalTrials
Oligodendroglioma 1 D009837 ClinicalTrials
Genital Neoplasms, Female 1 D005833 ClinicalTrials
Diffuse Intrinsic Pontine Glioma 1 D000080443 ClinicalTrials
Peritoneal Neoplasms 1 D010534 ClinicalTrials
Uterine Cervical Neoplasms 1 D002583 ClinicalTrials
Glioma 1 D005910 ClinicalTrials
Urethral Neoplasms 1 D014523 ClinicalTrials
Lung Neoplasms 1 D008175 ClinicalTrials
Astrocytoma 1 D001254 ClinicalTrials
Astrocytoma 1 D001254 ClinicalTrials
Colonic Neoplasms 1 D003110 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
15.54
Respiratory, thoracic and mediastinal disorders
10.75
Gastrointestinal disorders
7.56
Investigations
6.82
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
6.25
Metabolism and nutrition disorders
5.74
Infections and infestations
5.69
Cardiac disorders
5.42
Renal and urinary disorders
5.03
Vascular disorders
4.96
Blood and lymphatic system disorders
4.79
Skin and subcutaneous tissue disorders
4.2
Nervous system disorders
3.68
Injury, poisoning and procedural complications
3.15
Immune system disorders
2.82
Musculoskeletal and connective tissue disorders
2.39

Cross References

Resources Reference
CAS NUMBER 162635-04-3
ChEBI 79699
ChEMBL CHEMBL1201182
DrugBank DB06287
DrugCentral 4161
EPA CompTox DTXSID2040945
FDA SRS 624KN6GM2T
Human Metabolome Database HMDB0015632
Guide to Pharmacology 5892
KEGG C15182
PubChem 6918289
SureChEMBL SCHEMBL18792